Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kaneski, C. R.
Right arrow Articles by Schiffmann, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaneski, C. R.
Right arrow Articles by Schiffmann, R.
Related Collections
Right arrow Metabolic disease (inherited)
Right arrow All Cerebrovascular disease/Stroke
Right arrow Infarction
NEUROLOGY 2006;67:2045-2047
© 2006 American Academy of Neurology
Brief Communications

Myeloperoxidase predicts risk of vasculopathic events in hemizgygous males with Fabry disease

C. R. Kaneski, MS, D. F. Moore, MD, PhD, DIC, M. Ries, MD, MHSc, G. C. Zirzow, BS and R. Schiffmann, MD, MHSc

From the Developmental and Metabolic Neurology Branch (C.R.K., M.R., G.C.Z., R.S.), National Institute of Neurological Disorders and Stroke National Institutes of Health, Bethesda, MD; and the Section of Neurology (D.F.M.), Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada.

Address correspondence and reprint requests to Dr. Raphael Schiffmann, National Institutes of Health, Building 10, Room 3D03, 9000 Rockville Pike, Bethesda, MD 20892-1260; e-mail: RS4e{at}nih.gov

Fabry disease results in a global vasculopathy leading to early-onset stroke and renal and cardiac failure. We found that random myeloperoxidase in serum and plasma was significantly elevated in 73 consecutive male patients with Fabry disease. Random serum myeloperoxidase level in men predicted the risk of a Fabry vasculopathy–related event in subsequent years. Long-term enzyme replacement therapy did not reduce myeloperoxidase level or eliminate the risk of vasculopathic events.

Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the December 12 issue to find the title link for this article.

Supported by the Intramural Program of the NINDS.

Disclosure: The authors report no conflicts of interest.

Received June 6, 2006. Accepted in final form August 3, 2006.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by AAN Enterprises, Inc.